United Therapeutics registers two SUMMIT trials of inhaled treprostinil SMI for PH-COPD
Two new registry listings outline a Phase 2 safety study and a long-term open-label extension of treprostinil delivered by soft mist inhaler in pulmonary hypertension associated with COPD.
United Therapeutics posted two new clinical trial registrations for its treprostinil soft mist inhaler (SMI) program in pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD), both listed as not yet recruiting as of November 6, 2026.
- "SUMMIT 201" (NCT07923591, SMI-PH-201) is a Phase 2 study evaluating the safety and tolerability of treprostinil administered with a soft mist inhaler over 16 weeks in approximately 40 participants with PH-COPD.1 The study is randomized, double-blind, and placebo-controlled, assigning participants 1:1 to treprostinil SMI or placebo, with secondary endpoints evaluating exercise capacity and NT-proBNP.1 Start is estimated for November 2026, with primary completion estimated for May 2028.
- "SUMMIT OLE" (NCT07923526, SMI-PH-202) is an open-label extension study whose purpose is to evaluate the long-term impact of treprostinil SMI on safety and efficacy by providing it to PH-COPD patients who participated in a preceding Phase 2 or 3 study.2 The trial is designed as a single-arm study with inherently no control or comparator arm,2 enrolling an estimated 400 participants who may remain in the study for up to 7.5 years.2 Start is estimated for March 2027, with primary and study completion estimated for September 2034.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.